Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Radiology Supervision Contrast topic
No spam. Unsubscribe anytime.
Bill would allow virtual (general) supervision for IV contrast to expand imaging access
Summary
House Bill 1546 would allow certain radiologic technologists to administer IV contrast under general (virtual) supervision, provided a supervising physician is available within 30 miles to respond to on‑site patient needs.
Get email alerts on the Radiology Supervision Contrast topic
No spam. Unsubscribe anytime.
The House Health Care & Wellness Committee on Feb. 5 heard House Bill 1546, which would authorize diagnostic radiologic technologists, therapeutic radiologic technologists and MRI technologists to perform intravenous contrast procedures under general supervision rather than the current direct‑supervision standard.
Committee staff explained that the bill changes the supervision standard from "direct" — a physician on the premises who is quickly available — to "general supervision," which the bill defines as care provided under the overall direction and control of a physician who is not physically required to be present but must be within 30 miles and able to respond to on‑site patient care as needed.
Proponents included radiologists from private practices and hospital systems who testified that allowing virtual supervision would increase access to contrast‑enhanced CT and MRI studies in rural and underserved areas, enable evening and weekend imaging slots, and help address radiologist shortages. Lloyd Stambaugh and Dr. Seth Urban, both radiologists, noted that modern contrast agents have much lower severe reaction rates than earlier agents and that technological approaches used elsewhere have preserved safety while expanding access.
Opponents were limited in number during the Feb. 5 hearing; hospital representatives indicated they would work with sponsors on clarifying language, including how an adverse‑reaction response would be handled and how virtual supervision would be documented. Supporters told the committee they plan to propose technical amendments clarifying the process for adverse reactions and documentation.
No committee vote was taken on HB 1546 during the Feb. 5 hearing.
